Mavacoxib

Mavacoxib
Clinical data
Trade names Trocoxil
AHFS/Drugs.com International Drug Names
ATCvet code
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
ChEBI
Chemical and physical data
Formula C16H11F4N3O2S
Molar mass 385 g/mol
3D model (JSmol)

Mavacoxib (trade name Trocoxil) is a veterinary drug used to treat pain and inflammation in dogs with degenerative joint disease.[1] It acts as a COX-2 inhibitor.[2]

Mavacoxib, along with other COX-2 selective inhibitors, celecoxib, valdecoxib, and parecoxib, were discovered by a team at the Searle division of Monsanto led by John Talley.[3][4]

References

  1. ↑ European Public Assessment Report (EPAR): Trocoxil, European Medicines Agency
  2. ↑ Cox, S. R.; Lesman, S. P.; Boucher, J. F.; Krautmann, M. J.; Hummel, B. D.; Savides, M.; Marsh, S.; Fielder, A.; Stegemann, M. R. (2010). "The pharmacokinetics of mavacoxib, a long-acting COX-2 inhibitor, in young adult laboratory dogs". Journal of Veterinary Pharmacology and Therapeutics. 33 (5): 461–70. doi:10.1111/j.1365-2885.2010.01165.x. PMID 20840390.
  3. ↑ Langreth, Robert (June 23, 2003). "The Chemical Cobbler". Forbes.
  4. ↑ "Dr. John Talley: 2001 St. Louis Awardee" (PDF). Chemical Bond. St. Louis Section, American Chemical Society. 52 (5): 2. May 2001. Archived from the original (PDF) on 15 April 2018.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.